Search hospitals > Manitoba > WINNIPEG
CancerCare Manitoba
Claim this profileWINNIPEG, Manitoba R3E 0V9
Global Leader in Leukemia
Global Leader in Lymphoma
Conducts research for Lymphoid Leukemia
Conducts research for Breast Cancer
Conducts research for Cancer
433 reported clinical trials
19 medical researchers
Summary
CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Leukemia, Lymphoma, Lymphoid Leukemia, Breast Cancer, Cancer and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 424 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Kristjan Paulson, and Versha Banerji.Area of expertise
1Leukemia
Global LeaderStage II
Stage I
Philadelphia chromosome positive
2Lymphoma
Global LeaderStage II
Stage IV
Stage I
Top PIs
Ashley ChopekCancerCare Manitoba4 years of reported clinical research
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
27 reported clinical trials
73 drugs studied
Issai M. VananCancerCare Manitoba4 years of reported clinical research
Studies Tumors
Studies Leukemia
25 reported clinical trials
69 drugs studied
Kristjan PaulsonCancerCare Manitoba5 years of reported clinical research
Studies Leukemia
Studies Graft-versus-Host Disease
4 reported clinical trials
5 drugs studied
Versha BanerjiCancer Care Manitoba2 years of reported clinical research
Studies Leukemia
Studies Lymphoma
4 reported clinical trials
8 drugs studied
Clinical Trials running at CancerCare Manitoba
Lymphoma
Leukemia
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Small Cell Lung Cancer
Ovarian Tumors
Germ Cell Tumors
Cancer
Neuroendocrine Tumors
Acute Leukemia
Nivolumab + Chemo-Immunotherapy
for Large B-Cell Lymphoma
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
Recruiting2 awards Phase 321 criteria
Brentuximab Vedotin + Nivolumab
for Hodgkin's Lymphoma
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Recruiting2 awards Phase 3
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting2 awards Phase 31 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at CancerCare Manitoba?
CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Leukemia, Lymphoma, Lymphoid Leukemia, Breast Cancer, Cancer and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 424 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Kristjan Paulson, and Versha Banerji.
Where is CancerCare Manitoba located?
CancerCare Manitoba is situated at 675 McDermot Avenue, Winnipeg, MB, near the intersection of McDermot Avenue and William Avenue.
Who should I call to ask about financial aid or insurance network?
**CancerCare Manitoba Financial Assistance and Insurance Inquiries:**
- For financial assistance, contact the CancerCare Co-Payment Assistance Foundation at 800-813-HOPE (4673). They provide support for transportation, home care, child care, and pet assistance for those with a confirmed cancer diagnosis, undergoing active treatment, residing in the U.S. or Puerto Rico, and meeting Federal Poverty Limit guidelines.
- CancerCare's "Managing the Cost of Cancer" booklet and the Purpose in Planning Coping Circle Series - Part I workshop offer resources and tips for managing cancer care costs and financial planning.
- In Manitoba, the Canadian Cancer Society's Access to Care program offers treatment-related travel and accommodation assistance for eligible individuals. CancerCare Manitoba provides free counseling on Manitoba’s Insured Health Benefits.
- The Government of Canada supports cancer patients through Employment Insurance (EI), sickness benefits, caregiving benefits, tax deductions, and the Canada Pension Plan (CPP).
What insurance does CancerCare Manitoba accept?
CancerCare Manitoba is a provincially mandated cancer agency offering clinical services to both children and adults, covered under Manitoba Health for Manitoba residents. This coverage includes physicians' services, surgery, anaesthesia, x-ray, and laboratory services in approved facilities. For out-of-province and out-of-country care, Manitoba Health provides certain coverages, but additional health insurance is recommended to cover excluded services and potential extra charges.
What awards or recognition has CancerCare Manitoba received?
CancerCare Manitoba Hospital, located in Winnipeg, Manitoba, benefits from substantial funding provided by the CancerCare Manitoba Foundation, thanks to the generous support of Manitobans. This financial backing has facilitated the hospital in leading and participating in clinical trials, funding local cancer research, and enhancing care and services for patients. The hospital's Research Institute, supported by over 40 scientists, concentrates on a broad spectrum of inquiries related to cancer and blood disorders.